Sansbury, Griffin M.
Pence, Brian W.
Zimba, Chifundo
Yanguela, Juan
Landrum, Kelsey
Matewere, Maureen
Mbota, MacDonald
Malava, Jullita K.
Tikhiwa, Harriet
Morrison, Abigail M.
Akiba, Christopher F.
Gaynes, Bradley N.
Udedi, Michael
Hosseinipour, Mina C.
Stockton, Melissa A.
Funding for this research was provided by:
National Institute of Mental Health (U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202-04S1, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01, U19MH113202–01)
Article History
Received: 9 June 2023
Accepted: 17 November 2023
First Online: 14 December 2023
Declarations
:
: The parent SHARP trial and endpoint evaluation were approved by the University of North Carolina Biomedical Institutional Review Board (Chapel Hill, NC, USA; ID 250449) and the Malawian National Health Sciences Research Committee (Lilongwe, Malawi; #1925). All research activities adhered to US and Malawian ethical standards. All the procedures were followed in accordance with the relevant guidelines. All study participants provided written informed consent.
: Not applicable.
: The authors declare that they have no competing interests.